Avalon Globocare Corp
NASDAQ:ALBT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avalon Globocare Corp
Long-Term Investments
Avalon Globocare Corp
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Avalon Globocare Corp
NASDAQ:ALBT
|
Long-Term Investments
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Long-Term Investments
$134m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-12%
|
|
|
CVS Health Corp
NYSE:CVS
|
Long-Term Investments
$32.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Cigna Corp
NYSE:CI
|
Long-Term Investments
$18.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Long-Term Investments
$153.9m
|
CAGR 3-Years
33%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Avalon Globocare Corp
Glance View
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm is focused on the fields of cellular immunotherapy, including CAR-T/NK; exosome technology (ACTEX), and COVID-19-related vaccine and therapeutics through its subsidiaries. The company operates through two business segments: real property operating segment and medical related consulting services segment. The firm also provides strategic advisory and outsourcing services to facilitate and improve its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its clinical programs include AVA-001, ACTEX, FLASH-CAR, and AVA-Trap.
